Fulgent Genetics, Inc.
NASDAQ Global MarketTotal Valuation
Fulgent Genetics, Inc. carries a market capitalization of 515.19M, placing it among publicly traded companies globally. Its enterprise value stands at 217.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 515.19M |
| Enterprise Value | 217.48M |
Share Statistics
Fulgent Genetics, Inc. currently has 28.85M shares outstanding.
| Shares Outstanding | 28.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.53, and the price-to-book ratio stands at 0.97.
| PE Ratio | N/A |
| PS Ratio | 1.53 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | -7.30 |
| P/OCF Ratio | -5.43 |
Enterprise Valuation
| EV / Sales | 0.68 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 16.84 |
Financial Position
Fulgent Genetics, Inc. maintains a current ratio of 5.31, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.95, indicating moderate leverage, while an interest coverage ratio of -1,047.68 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.31 |
| Quick Ratio | 3.91 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | -0.12 |
| Interest Coverage | -1,047.68 |
Financial Efficiency
| Return on Equity (ROE) | -13.62 |
| Return on Assets (ROA) | -6.25 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 18.99 |
Taxes
| Income Tax | -9.27M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Fulgent Genetics, Inc.'s stock has declined approximately -14.31271% over the past 52 weeks. The 50-day moving average sits at 16.13, while the 200-day moving average is 21.90.
| Beta (5Y) | N/A |
| 52-Week Price Change | -14.31271% |
| 50-Day Moving Average | 16.13 |
| 200-Day Moving Average | 21.90 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Fulgent Genetics, Inc. generated 320.35M in revenue and converted that into -73.81M in net income, yielding earnings per share of -2.44. EBITDA reached -81.72M, while operating income came in at -105.92M.
| Revenue | 320.35M |
| Gross Profit | 124.02M |
| Operating Income | -105.92M |
| Pretax Income | -84.28M |
| Net Income | -73.81M |
| EBITDA | -81.72M |
| EBIT | -105.92M |
| Earnings Per Share (EPS) | -2.44 |
Balance Sheet
Fulgent Genetics, Inc. holds 276.30M in cash and equivalents against 9.90M in total debt, resulting in a net debt position of -21.44M. Total book value stands at 505.13M, with working capital of 388.91M providing operational flexibility.
| Cash & Cash Equivalents | 276.30M |
| Total Debt | 9.90M |
| Net Debt | -21.44M |
| Equity (Book Value) | 505.13M |
| Book Value Per Share | 16.41 |
| Working Capital | 388.91M |
Cash Flow
Fulgent Genetics, Inc. produced -90.11M in operating cash flow over the past twelve months. After subtracting -23.06M in capital expenditures, free cash flow totaled -113.17M - equivalent to -3.68 per share.
| Operating Cash Flow | -90.11M |
| Capital Expenditures | -23.06M |
| Free Cash Flow | -113.17M |
| FCF Per Share | -3.68 |
Margins
Fulgent Genetics, Inc. operates with a gross margin of 38.71, reflecting its pricing power and cost economics. The operating margin of -33.07 and net profit margin of -23.04 provide insight into operational efficiency.
| Gross Margin | 38.71 |
| Operating Margin | -33.07 |
| Pretax Margin | -26.31 |
| Profit Margin | -23.04 |
| EBITDA Margin | -25.51 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 9.90 |
| FCF Yield | -13.70 |
Scores
Fulgent Genetics, Inc. posts an Altman Z-Score of 3.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.82 |